Ser303
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser303  -  AML1 iso8 (human)

Site Information
VHPAtPIsPGRASGM   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 454401
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 8 , 9 , 10 ) , immunoprecipitation ( 2 ) , mass spectrometry ( 4 , 11 , 12 ) , mutation of modification site ( 2 , 5 , 6 , 7 , 8 , 9 , 10 ) , phospho-antibody ( 3 , 5 , 6 , 7 , 8 ) , western blotting ( 3 , 6 , 8 )
Disease tissue studied:
leukemia ( 3 , 10 , 12 ) , acute myelogenous leukemia ( 3 ) , chronic lymphocytic leukemia ( 12 ) , chronic myelogenous leukemia ( 10 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
CBFB (human) ( 3 ) , MYH11 (human) ( 3 )
Putative in vivo kinases:
ERK1 (human) ( 10 ) , ERK2 (human) ( 10 )
Kinases, in vitro:
CDK1 (human) ( 7 , 8 ) , CDK2 (human) ( 8 ) , CDK6 (human) ( 8 )
Treatments:
alsterpaullone ( 8 ) , Cdk2_inhibitor_II ( 8 ) , cell cycle regulated ( 7 ) , nocodazole ( 7 , 8 ) , PD98059 ( 10 ) , phorbol_ester ( 7 , 10 ) , purvalanol ( 7 ) , seliciclib ( 6 , 8 )

Downstream Regulation
Effects of modification on AML1 iso8:
activity, induced ( 6 ) , molecular association, regulation ( 2 ) , phosphorylation ( 8 ) , protein degradation ( 8 , 9 )
Effects of modification on biological processes:
cell growth, altered ( 2 ) , cell growth, induced ( 6 ) , transcription, induced ( 6 )
Inhibit interaction with:
HDAC1 (human) ( 2 ) , HDAC3 (human) ( 2 )

References 

1

Yoshimi M, et al. (2012) Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. Eur J Immunol 42, 1044-50
22531928   Curated Info

2

Guo H, Friedman AD (2011) Phosphorylation of RUNX1 by cyclin-dependent kinase reduces direct interaction with HDAC1 and HDAC3. J Biol Chem 286, 208-15
21059642   Curated Info

3

Kamikubo Y, et al. (2010) Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1. Cancer Cell 17, 455-68
20478528   Curated Info

4

Moritz A (2008) CST Curation Set: 5058; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

5

Tachibana M, et al. (2008) Phosphorylation of Runx1 at Ser249, Ser266, and Ser276 is dispensable for bone marrow hematopoiesis and thymocyte differentiation. Biochem Biophys Res Commun 368, 536-42
18261462   Curated Info

6

Zhang L, Fried FB, Guo H, Friedman AD (2008) Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation. Blood 111, 1193-200
18003885   Curated Info

7

Wang S, Zhang Y, Soosairajah J, Kraft AS (2007) Regulation of RUNX1/AML1 during the G2/M transition. Leuk Res 31, 839-51
17023045   Curated Info

8

Biggs JR, et al. (2006) AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol Cell Biol 26, 7420-9
17015473   Curated Info

9

Biggs JR, et al. (2005) Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association. Mol Cancer Res 3, 391-401
16046550   Curated Info

10

Zhang Y, Biggs JR, Kraft AS (2004) Phorbol ester treatment of K562 cells regulates the transcriptional activity of AML1c through phosphorylation. J Biol Chem 279, 53116-25
15475366   Curated Info

11

Guo A (2004) CST Curation Set: 330; Year: 2004; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

12

Goss V (2004) CST Curation Set: 333; Year: 2004; Biosample/Treatment: blood, B lymphoid/-; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info